There are 410 resources available
2O - Phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR mutant non-small cell lung cancer (NSCLC): Analysis of adverse events (AEs)
Presenter: Saumil Ghandi
Session: Proffered Paper 1
Resources:
Abstract
Radon and other risk factors in lung cancer
Presenter: Laura Mezquita
Session: Lung cancer beyond tobacco: Impact of environmental and other risk factors
Resources:
Slides
Webcast
Invited Discussant 1O and 2O
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper 1
Resources:
Slides
Webcast
Q&A
Presenter: Fernando Lopez-Rios
Session: Updates on molecular diagnosis
Resources:
Webcast
Air pollution and lung cancer
Presenter: Christine Berg
Session: Lung cancer beyond tobacco: Impact of environmental and other risk factors
Resources:
Slides
Webcast
Q&A
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper 1
Resources:
Webcast
Lung cancer prevention: Patients/advocates perspective
Presenter: Anne-Marie Baird
Session: Lung cancer beyond tobacco: Impact of environmental and other risk factors
Resources:
Slides
Webcast
3O - Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
Presenter: Pilar Garrido Lopez
Session: Proffered Paper 1
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: Laura Mezquita
Session: Lung cancer beyond tobacco: Impact of environmental and other risk factors
Resources:
Webcast
4O - Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
Presenter: David Waterhouse
Session: Proffered Paper 1
Resources:
Abstract
Slides
Webcast